Please assess the completion status of the following clinical trial:

Trial Title: Lonafarnib for Chronic Hepatitis D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Age 18 years or above, male or female.~ 2. Serum alanine or aspartate aminotransferase activities above the upper limit of normal (ALT \> 41 or AST \> 31 U/L) on an average of three determinations taken during the previous 6 months. The mean of the three determinations will be defined as baseline levels.~ 3. Presence of anti-HDV in serum.~ 4. Evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a necroinflammatory score in histology activity index of at least 5 (out of a maximum of 18) and at least 1 for hepatic fibrosis (out of a maximum of 6).~ 5. Presence of HDV antigen in liver tissue or HDV RNA in serum.~ 6. Written informed consent.~EXCLUSION CRITERIA:~1. Decompensated liver disease, defined by bilirubin \> 4mg/dL, albumin \< 3.0 gm/dL, prothrombin time \> 2 sec prolonged, or history of bleeding esophageal varices, ascites or hepatic encephalopathy. Laboratory abnormalities that are not thought to be due to liver disease may not necessarily require exclusion. Patients with ALT levels greater than 1000 U/L (\> 25 times ULN) will not be enrolled but may be followed until three determinations are below this level.~2. Pregnancy or inability to practice adequate contraception, in women of childbearing potential or in spouses of such women. Adequate contraception is defined as vasectomy in men, tubal ligation in women, or use of two barrier methods such as condoms and spermicide combination, birth control pills, an intrauterine device, Depo-Provera, or Norplant.~3. Significant systemic or major illnesses other than liver disease, including, but not limited to, congestive heart failure, renal failure (eGFR \< 50 ml/min), organ transplantation, serious psychiatric disease or depression (only if felt to be at high risk by the NIH psychiatric consultation service), and active coronary artery disease.~4. Systemic immunosuppressive therapy within the previous 2 months.~5. Evidence of another form of liver disease in addition to viral hepatitis (for example autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson disease, alcoholic liver disease, nonalcoholic steatohepatitis (but not steatosis), hemochromatosis, or alpha-1-antitrypsin deficiency).~6. Active substance abuse, such as alcohol, inhaled or injection drugs within the previous year.~7. Evidence of hepatocellular carcinoma.~8. Evidence of concurrent hepatitis C infection with positive serum HCV RNA.~9. Any experimental therapy apart from pegylated interferon within 6 months prior to enrollment.~10. Diagnosis of malignancy in the five years prior to the enrollment with exception granted to superficial dermatologic malignancies.~11. Evidence of HIV co-infection; HIV (Omega) antibody positivity on serum testing.~12. Concurrent usage of statins as these drugs inhibit mevalonate synthesis which reduces protein prenylation.~13. Concurrent usage of moderate and strong CYP3A inhibitors and inducers.~14. Inability to understand or sign informed consent.~15. Any other condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control
- Group 1 (Type: EXPERIMENTAL): lonafarnib 100mg
- Group 2 (Type: EXPERIMENTAL): lonafarnib 200mg

Based on this trial design, predict the completion outcome and termination type (if applicable).